Go Pro
→ They proved it worked in '76. Then buried it. (From Behind the Markets) (Ad)tc pixel Free KTTAW Stock Alerts

Pasithea Therapeutics (KTTAW) Competitors

$0.0047 0.00 (-28.79%)
Closing price 06/29/2026 03:59 PM Eastern
Extended Trading
$0.00 0.00 (-0.64%)
As of 03:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

KTTAW vs. AIMDW, ALVOW, ARAV, ACABW, and BFRIW

Should you buy Pasithea Therapeutics stock or one of its competitors? MarketBeat compares Pasithea Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pasithea Therapeutics include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Biofrontera (BFRIW). These companies are all part of the "pharmaceutical products" industry.

How does Pasithea Therapeutics compare to Ainos?

Ainos (NASDAQ:AIMDW) and Pasithea Therapeutics (NASDAQ:KTTAW) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

In the previous week, Ainos had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 2 mentions for Ainos and 1 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 1.89 beat Ainos' score of 1.43 indicating that Pasithea Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Ainos Positive
Pasithea Therapeutics Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ainos$18.11KN/AN/AN/AN/A
Pasithea TherapeuticsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
AinosN/A N/A N/A
Pasithea Therapeutics N/A N/A N/A

Summary

Ainos beats Pasithea Therapeutics on 2 of the 3 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Alvotech?

Alvotech (NASDAQ:ALVOW) and Pasithea Therapeutics (NASDAQ:KTTAW) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$559.42MN/AN/AN/AN/A
Pasithea TherapeuticsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
AlvotechN/A N/A N/A
Pasithea Therapeutics N/A N/A N/A

In the previous week, Alvotech had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 2 mentions for Alvotech and 1 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 1.89 beat Alvotech's score of 0.93 indicating that Pasithea Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Alvotech Positive
Pasithea Therapeutics Very Positive

Summary

Alvotech beats Pasithea Therapeutics on 2 of the 3 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Aravive?

Pasithea Therapeutics (NASDAQ:KTTAW) and Aravive (NASDAQ:ARAV) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pasithea TherapeuticsN/AN/AN/AN/AN/A
AraviveN/AN/AN/A-$0.90N/A

Company Net Margins Return on Equity Return on Assets
Pasithea TherapeuticsN/A N/A N/A
Aravive N/A N/A N/A

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Pasithea Therapeutics had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for Pasithea Therapeutics and 0 mentions for Aravive. Pasithea Therapeutics' average media sentiment score of 1.89 beat Aravive's score of 0.00 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Pasithea Therapeutics Very Positive
Aravive Neutral

Summary

Pasithea Therapeutics and Aravive tied by winning 2 of the 4 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Atlantic Coastal Acquisition Corp. II?

Pasithea Therapeutics (NASDAQ:KTTAW) and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pasithea TherapeuticsN/AN/AN/AN/AN/A
Atlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Pasithea TherapeuticsN/A N/A N/A
Atlantic Coastal Acquisition Corp. II N/A N/A N/A

In the previous week, Pasithea Therapeutics had 1 more articles in the media than Atlantic Coastal Acquisition Corp. II. MarketBeat recorded 1 mentions for Pasithea Therapeutics and 0 mentions for Atlantic Coastal Acquisition Corp. II. Pasithea Therapeutics' average media sentiment score of 1.89 beat Atlantic Coastal Acquisition Corp. II's score of 0.00 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Pasithea Therapeutics Very Positive
Atlantic Coastal Acquisition Corp. II Neutral

Summary

Pasithea Therapeutics beats Atlantic Coastal Acquisition Corp. II on 2 of the 2 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Biofrontera?

Pasithea Therapeutics (NASDAQ:KTTAW) and Biofrontera (NASDAQ:BFRIW) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability.

Company Net Margins Return on Equity Return on Assets
Pasithea TherapeuticsN/A N/A N/A
Biofrontera N/A N/A N/A

In the previous week, Biofrontera had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 2 mentions for Biofrontera and 1 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 1.89 beat Biofrontera's score of 1.44 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Pasithea Therapeutics Very Positive
Biofrontera Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pasithea TherapeuticsN/AN/AN/AN/AN/A
Biofrontera$43.20MN/AN/AN/AN/A

Summary

Biofrontera beats Pasithea Therapeutics on 2 of the 3 factors compared between the two stocks.

Get Pasithea Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KTTAW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KTTAW vs. The Competition

Export
MetricPasithea TherapeuticsBiotechnology IndustryMedical SectorNASDAQ Exchange
Market CapN/A$500.08M$6.84B$12.20B
Dividend YieldN/A3.87%2.66%6.22%
P/E RatioN/A3.1726.0424.37
Price / SalesN/A6,732.11547.53100.48
Price / CashN/A13.1329.0936.93
Price / BookN/A89.1010.976.49
Net IncomeN/A-$96.07M$3.57B$336.61M
7 Day PerformanceN/A0.70%2.50%1.20%
1 Month PerformanceN/A-0.35%0.86%0.20%
1 Year PerformanceN/A72.52%36.40%30.15%

Pasithea Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KTTAW
Pasithea Therapeutics
N/A$0.00
-28.8%		N/AN/A$0.00N/AN/A3
AIMDW
Ainos
N/A$0.15
-0.4%		N/A-16.0%$0.00$18.11KN/A40
ALVOW
Alvotech
N/A$0.33
-11.2%		N/AN/A$0.00$559.42MN/A4
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.00
flat		N/AN/A$0.00N/AN/A15

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:KTTAW) was last updated on 6/30/2026 by MarketBeat.com Staff.
From Our Partners
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
The startup growing 23 times faster than Nvidia
An official SEC document contains a name Elon Musk revealed on page 146 - a startup that one analyst believes ...
Brownstone Research | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company
We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...
Banyan Hill Publishing | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel